Anavex to present at the 42nd annual j.p. morgan healthcare conference

New york, jan. 03, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today announced its participation in the 42nd annual j.p. morgan healthcare conference. anavex's president and chief executive officer, christopher u missling, phd, is scheduled to present at the conference at the westin st. francis in san francisco, ca on january 11, 2024 at 10:30am pacific standard time (pst).
AVXL Ratings Summary
AVXL Quant Ranking